Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,983 Cr
P/E Ratio
23.67
P/B Ratio
2.62
Industry P/E
52.8
Debt to Equity
0.03
ROE
12.08 %
ROCE
16.82 %
Div. Yield
0 %
Book Value
20.75
EPS
2.38
CFO
₹206.08 Cr
EBITDA
₹865.28 Cr
Net Profit
₹464.83 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Morepen Lab
| -30.25 | 8.52 | -17.63 | 5.25 | 2.35 | 25.37 | 12.56 |
|
BSE Healthcare
| -5.48 | 1.35 | 0.22 | 22.74 | 20.05 | 23.06 | 9.77 |
|
BSE Small Cap
| -10.07 | 4.18 | -3.21 | 7.10 | 18.99 | 35.87 | 15.84 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Morepen Lab
| 59.19 | 28.27 | -32.71 | 84.73 | 95.54 | -29.48 | -43.64 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 306.00 | 3,338.15 | 63.39 | 24.79 | |
| 811.20 | 4,112.56 | 37.28 | 9.22 | |
| 2,315.70 | 3,819.44 | 48.27 | 23 | |
| 646.20 | 4,580.60 | -- | 4.09 |
2 min read•By News Desk
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic,... anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India. Read more
Incorporated
1984
Chairman
Sushil Suri
Managing Director
Sushil Suri
Group
Morepen
Headquarters
Solan Dist, Himachal Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Morepen Laboratories Ltd stood at ₹ 1,562 Cr as on 31-Dec-24
The share price of Morepen Laboratories Ltd is ₹54.52 (NSE) and ₹54.43 (BSE) as of 23-Apr-2025 IST. Morepen Laboratories Ltd has given a return of 2.35% in the last 3 years.
Morepen Laboratories Ltd has a market capitalisation of ₹ 2,983 Cr as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Morepen Laboratories Ltd is 2.62 times as on 23-Apr-2025, a 4% discount to its peers’ median range of 2.74 times.
The P/E ratio of Morepen Laboratories Ltd is 23.67 times as on 23-Apr-2025, a 55% discount to its peers’ median range of 52.80 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Morepen Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Morepen Laboratories Ltd.
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
The prominent promoters of Morepen Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
SCOPE CREDITS AND FINANCIAL SERVICES PVT. LTD. |
2.84%
|
|
CONCEPT CREDITS AND CONSULTANTS PVT. LTD. |
2.8%
|
|
BROOK INVESTMENTS AND FINANCIAL SERVICES PVT. LTD |
2.77%
|
|
SOLITARY INVESTMENTS AND FINANCIAL SERVICES PVT. LTD. |
2.76%
|
The chairman of the company is Sushil Suri, and the managing director is Sushil Suri.
There is no promoter pledging in Morepen Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,325
|
|
|
3,932
|
|
|
3,634
|
|
|
3,445
|
| Morepen Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.87
|
|
Operating margin(%)
|
8.94
|
|
Net Margin(%)
|
7.08
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Morepen Laboratories Ltd was ₹126 Cr.
₹0.04
(
